mogamulizumab (poteligeo) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL). The latter approval was based on study with 28 subjects.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

amg761 | amg 761 | amg-761 | km8761 | km-8761 | kw0761 | kw 0761 | kw-0761 | mogamulizumab | mogamulizumab (genetical recombination) | mogamulizumab-kpkc | poteligeo

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue